Literature DB >> 3403040

Cefetamet pivoxil: bacteriostatic and bactericidal activity of the free acid against 355 gram-negative rods.

P Hohl1, A von Graevenitz, J Zollinger-Iten.   

Abstract

The in vitro activity of the free acid of cefetamet pivoxil (Ro 15-8075) was tested against 355 clinical isolates, namely enteropathogenic bacteria, glucose non-fermentative gram-negative rods (excluding Pseudomonas aeruginosa) and Legionella pneumophila. Ceftriaxone was included in the study as reference compound. Although the free acid of the orally active cephalosporin was generally weaker than ceftriaxone, it inhibited 88.2% and 94.5% of Enterobacteriaceae and Vibrionaceae at a concentration of 4 mg/l and 8 mg/l or less, respectively. Campylobacter jejuni proved resistant to both compounds. The activity of the new compound against glucose non-fermentative gram-negative rods was generally insufficient to be of promise for broad clinical use. Although the compound was at least twofold more active than ceftriaxone against Pseudomonas acidovorans, Pseudomonas alcaligenes and Pseudomonas cepacia, the former was at least two dilution steps less active than the latter against 14 species of the other less common glucose non-fermentative organisms.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3403040     DOI: 10.1007/bf01644102

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  9 in total

1.  Preliminary antimicrobial susceptibility interpretive criteria for cefetamet (Ro 15-8074) and cefteram (Ro 19-5247) disk tests.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

2.  Antibiotics in Yersinia enterocolitica infections.

Authors:  J A Hoogkamp-Korstanje
Journal:  J Antimicrob Chemother       Date:  1987-07       Impact factor: 5.790

3.  In-vitro activity of Ro-15-8074, a new oral cephalosporin.

Authors:  M Peeters; P Piot
Journal:  J Antimicrob Chemother       Date:  1985-10       Impact factor: 5.790

4.  Occurrence and antimicrobial susceptibility of gram-negative nonfermentative bacilli in cystic fibrosis patients.

Authors:  J D Klinger; M J Thomassen
Journal:  Diagn Microbiol Infect Dis       Date:  1985-03       Impact factor: 2.803

5.  Pharmacokinetics of cefetamet (Ro 15-8074) and cefetamet pivoxil (Ro 15-8075) after intravenous and oral doses in humans.

Authors:  J R Koup; U C Dubach; R Brandt; R Wyss; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

6.  Failure of newer beta-lactam antibiotics for murine Yersinia enterocolitica infection.

Authors:  M R Scavizzi; J M Alonso; A M Philippon; A M Jupeau-Vessieres; A Guiyoule
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

7.  Comparison of antimicrobial susceptibility patterns of Campylobacter jejuni and Campylobacter coli.

Authors:  W L Wang; L B Reller; M J Blaser
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

8.  In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074).

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

9.  Susceptibility of Legionella pneumophila to twenty antimicrobial agents.

Authors:  P H Edelstein; R D Meyer
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

  9 in total
  4 in total

1.  Resignment: Infection is grateful to Prof. Alexander von Graevenitz.

Authors:  Johannes R Bogner
Journal:  Infection       Date:  2018-12       Impact factor: 3.553

2.  In vitro activities of fleroxacin, cefetamet, ciprofloxacin, ceftriaxone, trimethoprim-sulfamethoxazole, and amoxicillin-clavulanic acid against rare members of the family Enterobacteriaceae primarily of human (clinical) origin.

Authors:  P Hohl; J Lüthy-Hottenstein; J Zollinger-Iten; M Altwegg
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

Review 3.  Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

4.  Formulation development and rheological studies of palatable cefetamet pivoxil hydrochloride dry powder suspension.

Authors:  Sb Sateesha; Aj Rajamma; Hs Shekar; G Divakar
Journal:  Daru       Date:  2011       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.